0 6 Tissue tissue NN 7 13 factor factor NN 14 24 expression expression NN 25 27 of of IN 28 33 human human JJ 34 43 monocytes monocyte NNS 44 46 is be VBZ 47 57 suppressed suppress VBN 58 60 by by IN 61 84 lysophosphatidylcholine lysophosphatidylcholine NN 84 85 . . . 87 90 The the DT 91 101 expression expression NN 102 104 of of IN 105 111 tissue tissue NN 112 118 factor factor NN 119 120 ( ( ( 120 122 TF TF NNP 122 123 ) ) ) 123 124 , , , 125 128 the the DT 129 138 principal principal JJ 139 148 initiator initiator NN 149 151 of of IN 152 163 coagulation coagulation NN 163 164 , , , 165 167 is be VBZ 168 177 increased increase VBN 178 184 during during IN 185 197 inflammation inflammation NN 198 201 and and CC 202 217 atherosclerosis atherosclerosis NN 217 218 . . . 219 223 Both both DT 224 234 conditions condition NNS 235 238 are be VBP 239 247 promoted promote VBN 248 250 by by IN 251 274 lysophosphatidylcholine lysophosphatidylcholine NN 275 276 ( ( ( 276 282 lysoPC lysopc NN 282 283 ) ) ) 283 284 . . . 285 287 We we PRP 288 296 observed observe VBD 297 299 in in IN 300 303 the the DT 304 311 present present JJ 312 317 study study NN 318 322 that that IN 323 329 lysoPC lysopc NN 330 331 ( ( ( 331 332 1 1 CD 333 335 to to TO 336 338 10 10 CD 339 349 micromol/L micromol/l NN 349 350 ) ) ) 351 367 dose-dependently dose-dependently RB 368 375 reduced reduce VBD 376 378 TF TF NNP 379 387 activity activity NN 388 390 in in IN 391 396 human human JJ 397 406 monocytes monocyte NNS 406 407 , , , 408 410 as as IN 411 419 elicited elicit VBN 420 422 by by IN 423 441 lipopolysaccharide lipopolysaccharide NN 442 443 ( ( ( 443 448 LPS). LPS). NNP 449 477 Lysophosphatidylethanolamine Lysophosphatidylethanolamine NNP 478 479 ( ( ( 479 485 lysoPE lysoPE NNP 485 486 ) ) ) 487 490 and and CC 491 496 other other JJ 497 514 lysophospholipids lysophospholipid NNS 515 518 did do VBD 519 522 not not RB 523 529 affect affect VB 530 541 LPS-induced lps-induced JJ 542 544 TF tf NN 545 553 activity activity NN 554 556 of of IN 557 562 human human JJ 563 572 monocytes monocyte NNS 572 573 . . . 574 576 TF TF NNP 577 584 antigen antigen NN 585 595 expression expression NN 596 598 as as IN 599 607 elicited elicit VBN 608 610 by by IN 611 614 LPS LPS NNP 615 618 was be VBD 619 623 also also RB 624 631 lowered lower VBN 632 634 by by IN 635 641 lysoPC lysopc NN 641 642 . . . 643 655 Phospholipid Phospholipid NNP 656 664 analyses analysis NNS 665 674 indicated indicate VBD 675 676 a a DT 677 686 selective selective JJ 687 695 increase increase NN 696 698 in in IN 699 702 the the DT 703 709 lysoPC lysopc NN 710 717 content content NN 718 720 of of IN 721 724 the the DT 725 734 monocytes monocyte NNS 735 740 after after IN 741 754 preincubation preincubation NN 755 759 with with IN 760 763 the the DT 764 780 lysophospholipid lysophospholipid NN 780 781 . . . 782 788 LysoPC LysoPC NNP 789 798 inhibited inhibit VBD 799 802 the the DT 803 805 TF TF NNP 806 814 activity activity NN 815 817 of of IN 818 822 Mono Mono NNP 823 828 Mac-6 Mac-6 NNP 829 834 cells cell NNS 835 837 to to TO 838 839 a a DT 840 847 similar similar JJ 848 854 extent extent NN 855 857 as as IN 858 860 in in IN 861 864 the the DT 865 874 monocytes monocyte NNS 874 875 . . . 876 879 LPS lps NN 880 887 binding binding NN 888 890 to to TO 891 897 plasma plasma NN 898 906 membrane membrane NN 907 916 receptors receptor NNS 917 920 and and CC 921 936 internalization internalization NN 937 939 of of IN 940 943 LPS lps NN 944 948 into into IN 949 958 monocytes monocyte NNS 959 963 were be VBD 964 967 not not RB 968 976 affected affect VBN 977 979 by by IN 980 986 lysoPC lysopc NN 986 987 . . . 988 990 In in IN 991 999 contrast contrast NN 999 1000 , , , 1001 1013 LPS-mediated lps-mediated JJ 1014 1021 nuclear nuclear JJ 1022 1029 binding binding NN 1030 1032 of of IN 1033 1040 nuclear nuclear JJ 1041 1058 factor-kappaB/Rel factor-kappab/rel NN 1059 1061 to to TO 1062 1063 a a DT 1064 1075 TF-specific tf-specific JJ 1076 1082 kappaB kappab NN 1083 1087 site site NN 1088 1091 was be VBD 1092 1101 inhibited inhibit VBN 1102 1104 by by IN 1105 1111 lysoPC lysopc NN 1111 1112 . . . 1113 1122 Induction Induction NNP 1123 1125 of of IN 1126 1128 TF TF NNP 1129 1133 mRNA mrna NN 1134 1144 expression expression NN 1145 1147 by by IN 1148 1151 LPS LPS NNP 1152 1158 tended tend VBD 1159 1161 to to TO 1162 1164 be be VB 1165 1174 partially partially RB 1175 1182 reduced reduce VBN 1183 1185 by by IN 1186 1189 the the DT 1190 1206 lysophospholipid lysophospholipid NN 1206 1207 . . . 1208 1221 Preincubation preincubation NN 1222 1226 with with IN 1227 1233 lysoPC lysopc NN 1234 1243 increased increase VBD 1244 1253 monocytic monocytic JJ 1254 1258 cAMP camp NN 1259 1265 levels level NNS 1265 1266 . . . 1267 1277 Inhibition Inhibition NNP 1278 1280 of of IN 1281 1289 adenylyl adenylyl NN 1290 1297 cyclase cyclase NN 1298 1300 by by IN 1301 1313 pretreatment pretreatment NN 1314 1318 with with IN 1319 1340 2’-deoxy-3’-adenosine 2'-deoxy-3'-adenosine JJ 1341 1354 monophosphate monophosphate NN 1355 1364 partially partially RB 1365 1373 reversed reverse VBD 1374 1377 the the DT 1378 1388 inhibition inhibition NN 1389 1391 of of IN 1392 1394 TF TF NNP 1395 1403 activity activity NN 1404 1412 promoted promote VBN 1413 1415 by by IN 1416 1422 lysoPC lysopc NN 1422 1423 . . . 1424 1426 In in IN 1427 1437 conclusion conclusion NN 1437 1438 , , , 1439 1445 lysoPC lysopc NN 1446 1454 markedly markedly RB 1455 1464 decreases decrease VBZ 1465 1477 LPS-mediated lps-mediated JJ 1478 1480 TF TF NNP 1481 1491 expression expression NN 1492 1494 of of IN 1495 1500 human human JJ 1501 1510 monocytes monocyte NNS 1510 1511 , , , 1512 1515 the the DT 1516 1522 effect effect NN 1523 1531 probably probably RB 1532 1537 being be VBG 1538 1546 mediated mediate VBN 1547 1549 by by IN 1550 1554 both both CC 1555 1570 transcriptional transcriptional JJ 1571 1574 and and CC 1575 1594 posttranscriptional posttranscriptional JJ 1595 1605 mechanisms mechanism NNS 1605 1606 . . . 1607 1613 LysoPC LysoPC NNP 1614 1617 may may MD 1618 1622 thus thus RB 1623 1632 attenuate attenuate VB 1633 1643 activation activation NN 1644 1646 of of IN 1647 1658 coagulation coagulation NN 1659 1665 during during IN 1666 1678 inflammation inflammation NN 1679 1682 and and CC 1683 1698 atherosclerosis atherosclerosis NN 1698 1699 . . .